Company
Houston
Every investor coverage indicates participated in a round MD Anderson Cancer Center raised.
Companies MD Anderson Cancer Center acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming MD Anderson Cancer Center. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A profile of Chimeric Therapeutics and CEO Rebecca McQualter covering its CAR T cancer therapy, clinical progress, manufacturing partnerships, FDA designations, and path to Phase 2 trials by mid-2026.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
ChemGenex has begun enrolling patients in a second phase 2/3 trial testing Ceflatonin in chronic myeloid leukemia patients resistant to prior tyrosine kinase inhibitor treatment, with data expected in 2008.